Safety, pharmacokinetics and pharmacodynamics of multiple oral doses of apixaban, a factor Xa inhibitor, in healthy subjects
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Safety, pharmacokinetics and pharmacodynamics of multiple oral doses of apixaban, a factor Xa inhibitor, in healthy subjects
Authors
Keywords
-
Journal
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
Volume 76, Issue 5, Pages 776-786
Publisher
Wiley
Online
2013-03-05
DOI
10.1111/bcp.12106
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Apixaban, an oral, direct factor Xa inhibitor: single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects
- (2012) Charles Frost et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Antithrombotic Therapy for VTE Disease
- (2012) Clive Kearon et al. CHEST
- Apixaban in Patients with Atrial Fibrillation
- (2011) Stuart J. Connolly et al. NEW ENGLAND JOURNAL OF MEDICINE
- Apixaban versus Warfarin in Patients with Atrial Fibrillation
- (2011) Christopher B. Granger et al. NEW ENGLAND JOURNAL OF MEDICINE
- Evaluation of the anti-factor Xa chromogenic assay for the measurement of rivaroxaban plasma concentrations using calibrators and controls
- (2011) Genevieve Contant et al. THROMBOSIS AND HAEMOSTASIS
- Apixaban inhibition of factor Xa: Microscopic rate constants and inhibition mechanism in purified protein systems and in human plasma
- (2010) Joseph M. Luettgen et al. JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY
- Effects of the oral, direct factor Xa inhibitor rivaroxaban on commonly used coagulation assays
- (2010) A. HILLARP et al. JOURNAL OF THROMBOSIS AND HAEMOSTASIS
- Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial
- (2010) Michael Rud Lassen et al. LANCET
- Apixaban versus Enoxaparin for Thromboprophylaxis after Hip Replacement
- (2010) Michael Rud Lassen et al. NEW ENGLAND JOURNAL OF MEDICINE
- Assays for Measuring Rivaroxaban: Their Suitability and Limitations
- (2010) Edelgard Lindhoff-Last et al. THERAPEUTIC DRUG MONITORING
- Clinical laboratory measurement of direct factor Xa inhibitors: Anti-Xa assay is preferable to prothrombin time assay
- (2010) Zhaoqing Wang et al. THROMBOSIS AND HAEMOSTASIS
- In Vitro Assessment of Metabolic Drug-Drug Interaction Potential of Apixaban through Cytochrome P450 Phenotyping, Inhibition, and Induction Studies
- (2009) L. Wang et al. DRUG METABOLISM AND DISPOSITION
- Apixaban or Enoxaparin for Thromboprophylaxis after Knee Replacement
- (2009) Michael Rud Lassen et al. NEW ENGLAND JOURNAL OF MEDICINE
- Clinical Pharmacokinetics and Pharmacodynamics of the Oral Direct Thrombin??Inhibitor Dabigatran Etexilate
- (2008) Joachim Stangier CLINICAL PHARMACOKINETICS
- Arterial antithrombotic and bleeding time effects of apixaban, a direct factor Xa inhibitor, in combination with antiplatelet therapy in rabbits
- (2008) P. C. WONG et al. JOURNAL OF THROMBOSIS AND HAEMOSTASIS
- Apixaban, an oral, direct and highly selective factor Xa inhibitor:in vitro, antithrombotic and antihemostatic studies
- (2008) P. C. WONG et al. JOURNAL OF THROMBOSIS AND HAEMOSTASIS
- Efficacy and safety of the oral direct factorXa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose-ranging study
- (2008) et al. JOURNAL OF THROMBOSIS AND HAEMOSTASIS
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started